I have it on good authority from a number of reliable sources that Harte-Hanks valued Aberdeen at roughly $35-$45 million. One source pegged it at $42 million specifically. If this range -- or number -- is accurate, then it represents a decent multiple to Aberdeen's revenue (which I estimate in the $12-$15 million range). Of course this is all speculation as Harte-Hanks will not disclose the financial terms of the deal, despite numerous inbounds that friends have lobbed into their IR department. Also, it would appear as if the deal is not yet closed, so these numbers remain speculative, even if they are inline with the term sheet and letter of intent signed by both firms. One question that I have is whether Aberdeen's employees -- and past employees -- that exercised options or were granted common stock will actually realize material gains from the sale, given the preferred stock which is most likely outstanding with previous venture and angel investors. I do not know the answer to this, but given that the terms of the deal have not yet been disclosed, I think it is a reasonable question to ask, especially given the importance and reputation of the individual analyst -- not just the collective "fact-based" Aberdeen Borg -- in the firm's rebirth.